Year: 2022
Type: article
Abstract: PURPOSE: Genomic instability is a hallmark of cancer and targeting DNA damage response (DDR) is emerging as a promising therapeutic strategy in different solid tumors. The effectiveness of targeting DDR in colorectal cancer has not been extensively explored. EXPERIMENTAL DESIGN: We challenged 112 cell models recapitulating the genomic landscape of metastatic colorectal cancer with ATM, ATR, CHK1, WEE1, and DNA-PK inhibitors, in parallel with chemotherapeutic agents. We focused then on ATR inhibitors (ATRi) and, to identify putative biomarkers of response and resistance, we analyzed at multiple levels colorectal cancer models highly sensitive or resistant to these drugs. RESULTS: We found that around 30% of colorectal cancers, including those carrying KRAS and BRAF mutations and unresponsive to targeted agents, are sensitive to at least one DDR inhibitor. By investigating potential biomarkers of response to ATRi, we found that ATRi-sensitive cells displayed reduced phospho-RPA32 foci at basal level, while ATRi-resistant cells showed increased RAD51 foci formation in response to replication stress. Lack of ATM and RAD51C expression was associated with ATRi sensitivity. Analysis of mutational signatures and HRDetect score identified a subgroup of ATRi-sensitive models. Organoids derived from patients with metastatic colorectal cancer recapitulated findings obtained in cell lines. CONCLUSIONS: In conclusion, a subset of colorectal cancers refractory to current therapies could benefit from inhibitors of DDR pathways and replication stress. A composite biomarker involving phospho-RPA32 and RAD51 foci, lack of ATM and RAD51C expression, as well as analysis of mutational signatures could be used to identify colorectal cancers likely to respond to ATRi.
Source: Clinical Cancer Research
Authors: Erika Durinikova(Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Validation, Visualization, Writing – review & editing), Nicole M. Reilly(Data curation, Investigation, Methodology, Validation, Visualization), Kristi Buzo(Investigation), Elisa Mariella(Data curation, Formal analysis, Investigation, Methodology, Visualization), Rosaria Chilà, Annalisa Lorenzato(Data curation, Formal analysis, Methodology, Validation, Visualization), João M. L. Dias(Formal analysis, Investigation, Methodology), Gaia Grasso(Investigation, Visualization), Federica Pisati(Data curation, Formal analysis, Methodology, Visualization), Simona Lamba(Investigation, Methodology), Giorgio Corti(Investigation), Andrea Degasperi(Formal analysis, Investigation, Methodology), Carlotta Cancelliere(Resources), Gianluca Mauri(Investigation), Pietro Andrei(Data curation, Visualization), Michael Linnebacher(Resources), Silvia Marsoni(Writing – review & editing), Salvatore Siena(Funding acquisition, Resources), Andrea Sartore-Bianchi(Funding acquisition, Resources), Serena Nik-Zainal(Data curation, Formal analysis, Funding acquisition, Methodology, Supervision, Writing – review & editing), Federica Di Nicolantonio(Funding acquisition, Investigation), Alberto Bardelli(Conceptualization, Funding acquisition, Resources, Supervision, Writing – review & editing), Sabrina Arena(Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Project administration, Resources, Supervision, Visualization, Writing – original draft, Writing – review & editing)
Institutions: Candiolo Cancer Institute, University of Turin, IFOM, University of Cambridge, Cogentech S.R.L. Società Benefit a Socio Unico soggetta all’attività di direzione e coordinamento di IFOM - Istituto Fondazione di Oncologia Molecolare ETS (Italy), University of Milan, University of Rostock, Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
Language: English
Topic: DNA Repair Mechanisms
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: hybrid
Funders: Fondazione AIRC per la ricerca sul cancro ETS, Cancer Research UK, National Institute for Health and Care Research, European Commission, Associazione Italiana per la Ricerca sul Cancro, Fondazione Italiana per la Ricerca sul Cancro, Regione Lombardia, Fondazione Oncologia Niguarda Onlus, NIHR Cambridge Biomedical Research Centre, H2020 European Research Council
Awards: G1152858438, G1239396422, G156594879, G2555714370, G2809905454, G299057155, G356495653, G3640800619, G3653030475, G3994082246, G4267354033, G434337789, Targeting DNA repair pathways, sparking anti cancer immunity, G5366419201, G5718954505, Harnessing the power of cancer whole genome sequencing for clinical utility, G5986205792, G6238179109, G626503407, G63132147, G7116218047, G7212898136, G7388744371, G7513802581, G7598455352, G7756906289, G7885671846, G801137187, G8066471175, G8072394548, G8073119948, G8323115588, G8449251771, G8749953402, G934622242
OpenAlex ID: W4288042084
